Saturday February 16, 2019 16:50
Heathcare Press Release : 14 Feb 2017
60 years after the market launch of Contergan (active ingredient: thalidomide), the greatest pharmaceutical scandal in the Federal Republic of Germany continues to boil. A lawsuit will be heard in the Bonn Regional Court at 12:00 hrs on 15.2.2017 that is
- First Detailed Results from SWORD Clinical Trial Program Show Investigational Two-drug Combination as Effective as Three- or Four-drug Regimens as Maintenance Therapy in Patients who have Already Achieved Viral Suppression Janssen Sciences Ireland UC
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for